A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Clinical trial NCT01421186 · COMPLETED

Trial details

NCT number: NCT01421186
Sponsor: MorphoSys AG
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2011-07-01
Primary completion: 2020-08-01
Enrollment: 91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.